Domain Therapeutics
Created in 2008
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
7,936Activities
Technologies
Entity types
Location
850 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden CEDEX, France
Illkirch-Graffenstaden
France
Employees
Scale: 51-200
Estimated: 94
Engaged corporates
13
5 9Added in Motherbase
3 years, 6 months ago
biotech Value proposition
#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #immunosuppression
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.
Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
GPCR, immuno-oncology, and cancerOriginal language
#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #immunosuppression
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.
Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
Domain Therapeutics - A unique GPCR company in Immuno-Oncology
Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
https://www.domaintherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 7 Mar 2024 | | |
 Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Greater Paris University Hospitals - AP-HP Health, Hospitals and Health Care | Other 25 Jan 2024 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 14 Feb 2024 | | |
 CCI Alsace Eurométropole Chamber of commerce, Business Consulting and Services | CCI Alsace Eurométropole Chamber of commerce, Business Consulting and Services | Other 25 Oct 2023 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 19 May 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 30 Mar 2023 | | |
 La French Tech Est Startup accelerator & VC, French Tech, Business Consulting and Services | La French Tech Est Startup accelerator & VC, French Tech, Business Consulting and Services | Other 22 Mar 2023 | | |
 Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Other 16 Jul 2023 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 30 Mar 2023 | | |
 Omnes Startup accelerator & VC, Financial Services | Omnes Startup accelerator & VC, Financial Services | Other 1 Aug 2023 | | |